1 / 9

Targeted Therapy for Urothelial Carcinoma Explained

Erdafitinib is a novel compound that has recently become an object of interest in oncology due to its selective interaction with genetic abnormalities. Balversau00ae, is the brand name of novel molecule, erdafitinib, that directly targets FGFRs. Itu2019s an oral formulation mainly indicated for treatment of urothelial carcinoma of the urothelial tract.

ClivalDatabase
Download Presentation

Targeted Therapy for Urothelial Carcinoma Explained

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ERDAFITINIB TARGETED THERAPY FOR UROTHELIAL CARCINOMA EXPLAINED

  2. Introduction Erdafitinib is a novel compound that has recently become an object of interest in oncology due to its selective interaction with genetic abnormalities. Balversa®, is the brand name of novel molecule, erdafitinib, that directly targets FGFRs. It’s an oral formulation mainly indicated for treatment of urothelial carcinoma of the urothelial tract.

  3. Properties of Erdafitinib Erdafitinib is a tyrosine kinase inhibitor with some selectivity towards the FGFR1, FGFR2, FGFR3, and FGFR4 that are also collectively known as the fibroblast growth factor receptors. Interestingly, Erdafitinib blocks these receptors that inactivate many signaling pathways that are crucial for growth and development of the tumor.

  4. Mechanism of Action1 Erdafitinib mechanistically inhibits the enzymatic activity of FGFR1, FGFR2, FGFR3, and FGFR4. These receptors are involved with the process of cell proliferation, survival, as differentiation. Another is the ability of erdafitinib to suppress the signaling of FGFR which initially fosters development of tumour and ultimately decrease chance for the cancer cells to survive. 1 Inhibition of FGFR Signaling Induction of Apoptosis 2 Suppression of Angiogenesis 3 Mechanism Highlights

  5. Clinical Indications • Urothelial Carcinoma: Indicated for adult patients with locally advanced or metastatic bladder cancer harboring susceptible FGFR3 or FGFR2 alterations. • Combination Therapies: Researchers also wish to know how effective Erdafitinib is in combination with other treatments.

  6. Current Scenario Currently, erdafitinib is available in several countries, including the USA and EU.6 Ever increasing, erdafitinib serves as a standard of care for metastatic FGFR-altered bladder cancer. It has been established that the drug could still be applicable in other malignant diseases including breast and lung cancer. Scenario in India Access to Genetic Testing Relative scarcity of integrated service providers offering various forms of genetic tests. Cost of Treatment Unfortunately, erdafitinib is pricey and many patients do not get it through insurance.

  7. Future Directions Although todays Erdafitinib use is limited to specific cancers, further clinical research is underway for new indications and application. Incorporation of Erdafitinib to conventional cancer treatment regimens in India and across the globe will require improved education regarding the genetic testing and personalized therapy.

  8. Conclusion Erdafitinib is a new and breakthrough treatment of bladder cancer treatment that may be essential to patients with mutated genes. Specificity of the manner of action, proved effectiveness of the drug in clinical trials, and further research highlight its roles in a developing picture of cancer treatment.

  9. Contact Us info@lifescienceintellipedia.com +91-9990237670 C-89, Sector-65 Noida-U.P. 201301 (India) www.clival.com

More Related